Acosta, Erfe kinasuhan ng graft kaugnay ng Dengvaxia

By Len Montaño May 10, 2019 - 10:46 PM

Nahaharap sina Public Attorney’s Office (PAO) chief Persida Acosta at PAO Forensic Laboratory chief Dr. Erwin Erfe sa kasong graft at misuse of public office and public funds kaugnay ng kontrobersyal Dengvaxia.

Sa 20 pahinang reklamo na inihain sa Office of the Ombudsman, sinabi ni Atty. Wilfredo Garrido na nilabag nina Acosta at Erfe ang Anti-Graft and Corrupt Practices Act; falsification of public documents, malversation of public funds at illegal use of public funds or property.

“Acosta and her sidekick Erfe have fanned public anger, even creating hysteria, by painting the deaths as the result of a nefarious scheme to inject hundreds of thousands of children with an untested, experimental, ineffective and dangerous vaccine called Dengvaxia,” nakasaad sa reklamo.

Ayon kay Garrido, pinalaki nina Acosta at Erfe ang galit ng publiko sa Dengvaxia dahil pinalabas nila na ito ang dahilan ng pagkamatay ng mga naturukan ng bakuna na karamihan ay mga bata.

Nakasaad din sa reklamo na ang pagkabuo ng PAO Forensic Laboratory ay walang mandato mula sa Kongreso at hindi prescribed sa Administrative Code at PAO Law.

Binanggit din ng abogado ang kaso kung saan sinertipika ni Erfe ang resulta ng autopsy sa 13 anyos na batang babae na namatay noong January 2018 matapos maturukan ng Dengvaxia.

Wala pa namang pahayag o reaksyon mula sa kampo ng dalawa kaugnay ng reklamong kanilang kinakaharap.

TAGS: Atty. Percida Acosta, Atty. Wilfredo Garrido, bakuna, Dengvaxia, Dr. Erwin Erfe, graft, naturukan, ombudsman, Public Attorney's Office, Atty. Percida Acosta, Atty. Wilfredo Garrido, bakuna, Dengvaxia, Dr. Erwin Erfe, graft, naturukan, ombudsman, Public Attorney's Office

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.